US 11,938,138 B2
Methods for improved treatment of cancer
Robi Mitra, St. Louis, MO (US); Arnav Moudgil, St. Louis, MO (US); and Michael Nathaniel Wilkinson, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by Robi Mitra, St. Louis, MO (US); Arnav Moudgil, St. Louis, MO (US); and Michael Nathaniel Wilkinson, St. Louis, MO (US)
Filed on Jul. 9, 2021, as Appl. No. 17/371,750.
Claims priority of provisional application 63/049,658, filed on Jul. 9, 2020.
Prior Publication US 2022/0016131 A1, Jan. 20, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 31/506 (2006.01); A61K 31/551 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 31/506 (2013.01); A61P 35/00 (2018.01)] 15 Claims
 
1. A method of sensitizing cancer cells to a chemotherapeutic agent or treating a subject having cancer cells, the method comprising:
(i) administering an effective amount of a BET inhibiting agent to a subject or cancer cells, wherein the cancer cells comprise stem-like or CD24high cells regulated by BRD4, wherein the effective amount of the BET inhibiting agent converts the cancer cells into a more chemotherapeutically-sensitive state and reduces an amount of stem-like or CD24high cells, and wherein the BET inhibiting agent is selected from the group consisting of ABBV-075, BAY1238097, BI 894999, BMS-986158, CPI-0610, CPI203, FT-1101, GS-5829, GSK525762, GSK2820151, I-BET, I-BET762, I-BET151, INCB054329, JQ1, OTX015, MK-8628, MS417, PFI-1, PLX51107, RO6870810, RVX2135, TEN-010, and ZEN003694; and
(ii) administering a chemotherapeutic agent to the cancer cells.